Table of contents

Original Articles

• Proteomic analysis for early detection of ovarian cancer: A realistic approach? (1 October, 2003)

  E. V. Stevens, L. A. Liotta, E. C. Kohn
• What have we learned from ICON1 and ACTION? (1 October, 2003)

  N. Colombo, S. Pecorelli
• Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer (1 October, 2003)

  M. J. Piccart, K. Bertelsen, G. Stuart, J. Cassidy, C. Mangioni, E. Simonsen, K. James, S. Kaye, I. Vergote, R. Blom, R. Grimshaw, R. Atkinson, K. Swenerton, C. Trope, M. Nardi, J. Kaern, S. Tumolo, P. Timmers, J.-A. Roy, F. Lhoas, B. Lidvall, M. Bacon, A. Birt, J. Andersen, B. Zee, J. Paul, S. Pecorelli, B. Baron, W. Mcguire
• Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5 (1 October, 2003)

  M. A. Bookman, B. E. Greer, R. F. Ozols
• Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132 (1 October, 2003)

  F. M. Muggia
• The potential role of neoadjuvant chemotherapy in advanced ovarian cancer (1 October, 2003)

  M. Baekelandt
• Improving first-line therapy of advanced ovarian cancer – the AGO Ovarian Cancer Study Group perspective (1 October, 2003)

  A. Du Bois, J. Pfisterer, W. Meier, U. Wagner
• First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin (1 October, 2003)

  G. B. Kristensen, I. Vergote, G. Stuart, J. M. Del Campo, J. Kaern, A. B. Lopez, E. Eisenhauer, E. Aavall-Lundquist, M. Ridderheim, H. Havsteen, M. R. Mirza, M. Scheistroen, E. Vrdoljak
• The role of anthracyclines in second-line therapy of ovarian cancer (1 October, 2003)

  J. B. Vermorken
• Is combination chemotherapy superior to single-agent chemotherapy in second-line treatment? (1 October, 2003)

  A. González-Martín
• Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy (1 October, 2003)

  B. Sorbe
• Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy (1 October, 2003)

  M. J. Piccart, A. Floquet, G. Scarfone, P. H. B. Willemse, J. Emerich, I. Vergote, L. Giurgea, C. Coens, A. Awada, J. B. Vermorken
• Consolidation therapy revisited: intravenous chemotherapy (1 October, 2003)

  M. Markman
• Consolidation therapies revisited: weekly paclitaxel (1 October, 2003)

  S. Pecorelli, F. Odicino, G. Favalli
• Cost-effectiveness studies in ovarian cancer (1 October, 2003)

  T. D. Szucs, P. Wyss, K. J. Dedes
• Translational research in ovarian cancer: a must (1 October, 2003)

  T. C. Hamilton, D. C. Connolly, A. Y. Nikitin, K. Garson, B. C. Vanderhyden
• Systemic treatment policies in ovarian cancer: the next 10 years (1 October, 2003)

  J. J. Biagi, E. A. Eisenhauer
• Ovarian cancer treatment: what is new (1 October, 2003)

  A. Poveda